An Open-Label, Multi-Center Study to Evaluate the Safety of Long-Term Administration of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy.

Trial Profile

An Open-Label, Multi-Center Study to Evaluate the Safety of Long-Term Administration of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs TAK 128 (Primary)
  • Indications Diabetic neuropathies
  • Focus Adverse reactions
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 18 Dec 2008 Planned number of patients added to 221.
    • 07 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top